{"id":383468,"date":"2020-11-17T16:33:27","date_gmt":"2020-11-17T21:33:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=383468"},"modified":"2020-11-17T16:33:27","modified_gmt":"2020-11-17T21:33:27","slug":"aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/","title":{"rendered":"Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">AUSTIN, Texas<\/span>, <span class=\"xn-chron\">Nov. 17, 2020<\/span> \/PRNewswire\/ &#8212; Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in fireside chats at two investor conferences in <span class=\"xn-chron\">December 2020<\/span>. <\/p>\n<p>\n        <b>Conference Details<\/b>\n      <\/p>\n<p>Conference Name: Piper Sandler\u00a032nd\u00a0Annual\u00a0Virtual Healthcare Conference <br \/>Conference Date:\u00a0November 30 &#8211; December 3, 2020 <br \/>Fireside Chat Date\/Time: Available beginning <span class=\"xn-chron\">November 23, 2020<\/span><br \/>Presenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea&#8217;s president and chief executive officer <\/p>\n<p>Conference Name: Evercore ISI 3rd\u00a0Annual HealthCONx Conference <br \/>Conference Date:\u00a0December 1-3, 2020 <br \/>Fireside Chat Date\/Time: <span class=\"xn-chron\">December 1, 2020<\/span> at <span class=\"xn-chron\">4:20 p.m. EST<\/span><br \/>Presenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea&#8217;s president and chief executive officer <\/p>\n<p>To access the live and archived webcasts, visit the <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2984836-1&amp;h=2518654574&amp;u=http%3A%2F%2Fir.aegleabio.com%2Fevents-and-presentations%2Fupcoming-events&amp;a=Presentations+%26+Events\" rel=\"nofollow noopener noreferrer\">Presentations &amp; Events<\/a> section of the Company&#8217;s website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. An archived version of the webcasts will also be available through the Company&#8217;s website for a limited time following the conferences.<\/p>\n<p>\n        <b>About Aeglea BioTherapeutics<\/b>\n      <\/p>\n<p>Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea&#8217;s lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. The Company initiated a Phase 1\/2 clinical trial of ACN00177 for the treatment of Homocystinuria in the second quarter of 2020. Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2984836-1&amp;h=262478167&amp;u=http%3A%2F%2Faegleabio.com%2F&amp;a=http%3A%2F%2Faegleabio.com\" rel=\"nofollow noopener noreferrer\">http:\/\/aegleabio.com<\/a>. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder6813\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg\" title=\"(PRNewsfoto\/Aeglea BioTherapeutics, Inc.)\" alt=\"(PRNewsfoto\/Aeglea BioTherapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DA94876&amp;sd=2020-11-17\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences-301175289.html\">http:\/\/www.prnewswire.com\/news-releases\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences-301175289.html<\/a><\/p>\n<p>SOURCE  Aeglea BioTherapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DA94876&amp;Transmission_Id=202011171630PR_NEWS_USPR_____DA94876&amp;DateId=20201117\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire AUSTIN, Texas, Nov. 17, 2020 \/PRNewswire\/ &#8212; Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in fireside chats at two investor conferences in December 2020. Conference Details Conference Name: Piper Sandler\u00a032nd\u00a0Annual\u00a0Virtual Healthcare Conference Conference Date:\u00a0November 30 &#8211; December 3, 2020 Fireside Chat Date\/Time: Available beginning November 23, 2020Presenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea&#8217;s president and chief executive officer Conference Name: Evercore ISI 3rd\u00a0Annual HealthCONx Conference Conference Date:\u00a0December 1-3, 2020 Fireside Chat Date\/Time: December 1, 2020 at 4:20 p.m. ESTPresenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea&#8217;s president and chief executive officer To access the live &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-383468","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire AUSTIN, Texas, Nov. 17, 2020 \/PRNewswire\/ &#8212; Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in fireside chats at two investor conferences in December 2020. Conference Details Conference Name: Piper Sandler\u00a032nd\u00a0Annual\u00a0Virtual Healthcare Conference Conference Date:\u00a0November 30 &#8211; December 3, 2020 Fireside Chat Date\/Time: Available beginning November 23, 2020Presenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea&#8217;s president and chief executive officer Conference Name: Evercore ISI 3rd\u00a0Annual HealthCONx Conference Conference Date:\u00a0December 1-3, 2020 Fireside Chat Date\/Time: December 1, 2020 at 4:20 p.m. ESTPresenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea&#8217;s president and chief executive officer To access the live &hellip; Continue reading &quot;Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-17T21:33:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences\",\"datePublished\":\"2020-11-17T21:33:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\\\/\"},\"wordCount\":305,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1319229\\\/Aeglea_BioTherapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\\\/\",\"name\":\"Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1319229\\\/Aeglea_BioTherapeutics_Logo.jpg\",\"datePublished\":\"2020-11-17T21:33:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1319229\\\/Aeglea_BioTherapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1319229\\\/Aeglea_BioTherapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences - Market Newsdesk","og_description":"PR Newswire AUSTIN, Texas, Nov. 17, 2020 \/PRNewswire\/ &#8212; Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in fireside chats at two investor conferences in December 2020. Conference Details Conference Name: Piper Sandler\u00a032nd\u00a0Annual\u00a0Virtual Healthcare Conference Conference Date:\u00a0November 30 &#8211; December 3, 2020 Fireside Chat Date\/Time: Available beginning November 23, 2020Presenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea&#8217;s president and chief executive officer Conference Name: Evercore ISI 3rd\u00a0Annual HealthCONx Conference Conference Date:\u00a0December 1-3, 2020 Fireside Chat Date\/Time: December 1, 2020 at 4:20 p.m. ESTPresenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea&#8217;s president and chief executive officer To access the live &hellip; Continue reading \"Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-17T21:33:27+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences","datePublished":"2020-11-17T21:33:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/"},"wordCount":305,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/","name":"Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg","datePublished":"2020-11-17T21:33:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=383468"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383468\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=383468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=383468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=383468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}